Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Product Stability

Drug Product Stability

The long-term stability of drug products is critical to ensuring their quality, safety, and effectiveness over time. Stability directly influences a product's ability to maintain its intended characteristics, ensuring it performs as expected during its intended shelf life. Key attributes such as drug potency, impurities, dissolution, and other physicochemical measures of performance are tested to assess stability. These parameters indicate how well the product retains its quality over time and...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Pharmacodynamic Responses: Different Types

Pharmacodynamic Responses: Different Types

Pharmacodynamics is the scientific study of a drug's biochemical or physiological influence on the body. It categorizes responses into continuous, discrete (or categorical), and time-to-event outcomes. Continuous responses yield numerical values within a certain range, such as blood pressure readings and blood glucose levels, gauging the efficacy of antihypertensive and antidiabetic drugs. Discrete responses can be binary, indicating whether a drug has an effect or not, or ordinal, exemplifying...

Drug Nomenclature

Drug Nomenclature

During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Same author

Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.

Clinical pharmacology and therapeutics·2017

Same author

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

Clinical pharmacology and therapeutics·2017

Same author

Food Effect Studies for Oncology Drug Products.

Clinical pharmacology and therapeutics·2017

Same author

Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program.

Clinical pharmacology and therapeutics·2016

Same author

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

The pharmacogenomics journal·2016

Search research articles

Related Experiment Video

Updated: May 8, 2026

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

Are drug labels static or dynamic?

M J Seminerio¹, M J Ratain

¹Section of Hematology/Oncology, Department of Medicine and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, Illinois, USA. mseminerio@medicine.bsd.uchicago.edu

Clinical Pharmacology and Therapeutics

|August 22, 2013

Summary

Drug metabolism research is key to identifying drug-drug interactions (DDIs). The US Food and Drug Administration (FDA) should more consistently update drug labels with new pharmacokinetic findings, like those for imatinib.

More Related Videos

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

Related Experiment Videos

Last Updated: May 8, 2026

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

Area of Science:

Pharmacology
Drug Metabolism
Clinical Pharmacy

Background:

Accurate drug labels are crucial for safe medication use and preventing adverse drug events.
Drug metabolism studies inform potential drug-drug interactions (DDIs).
The US Food and Drug Administration (FDA) is responsible for ensuring drug labels reflect current scientific understanding.

Purpose of the Study:

To highlight recent findings on imatinib metabolism.
To advocate for a more rigorous and timely process for updating drug labels based on new research.
To emphasize the importance of pharmacokinetics in DDI identification.

Main Methods:

Review of recent peer-reviewed literature on imatinib metabolism.
Analysis of FDA drug label update consistency.
Commentary on current practices and proposed improvements.

Main Results:

Recent research provides new insights into imatinib's metabolic pathways.
The FDA's record of updating drug labels based on new findings is inconsistent.
Delays in label updates can hinder the identification and management of DDIs.

Conclusions:

A standardized and stringent protocol is needed for updating drug labels promptly.
Timely incorporation of pharmacokinetic data into drug labels is essential for patient safety.
Improved communication between researchers and regulatory bodies can enhance DDI management.